Catalog No.
Product Name
Application
Product Information
Citations
-
CRTh2 antagonist
CRTh2 antagonist 1 is a CRTh2 antagonist with an IC50 of 89 nM. -
EP1 antagonist
EP1-antanoist-1 is a EP1 antagonist with a pKi of 7.54 and an pIC50 of 8.5. -
EP4 partial agonist
GSK726701A is a novel prostaglandin E2 receptor 4 (EP4) partial agonist with a pEC50 of 7.4. -
PGI2 receptor agonist and vasodilator
Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation. -
EP4 receptor antagonist
BAY-1316957 is a highly potent and selective EP4 receptor antagonist with an IC50 of 15.3 nM. Good oral bioavailability. -
DP1 inhibitor
Laropiprant is used in combination with niacin to reduce blood cholesterol. Laropiprant acts as a DP1 antagonist, reducing the vasodilation. -
EP4 antagonist
MK-2894 sodium salt is a highly potent and selective second generation EP4 antagonist. -
EP4 antagonist
ONO-AE3-208 is an EP4 antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer. -
Thromboxane A2 synthesis inhibitor
Ozagrel is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor. -
Prostaglandin D2 receptor CRTH2 antagonist
CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective prostaglandin D2 receptor CRTH2 antagonist. -
Prostaglandin Receptor Agonist
Prostaglandin E2 is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation. -
DP1 receptor antagonist
Asapiprant, also known as S-555739, is a the potent and selective DP1 receptor antagonist. Asapiprant exhibited high affinity and selectivity for the DP1 receptor. -
CRTH2 antagonist
ACT-129968 is a potent and selective CRTH2 antagonist. -
EP2 Agonist
C-544326 is a potent and selective prostaglandin E2 receptor agonist with EC50 value of 2.8 nM. -
prostaglandin EP4 receptor antagonist
Grapiprant is a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. -
CRTH2 antagonist
OC 000459 is a potent, oral and selective CRTH2 (also known as DP2) antagonist. -
CRTh2 Receptor Antagonist
AZ-11665362 is a selective antagonist of the CRTh2 (DP2) receptor, exhibiting a potent IC50 of 2.6 nM. While it demonstrates slight activity towards aldose reductase and the serotonin transporter, it shows negligible inhibition of COX-1 and COX-2 enzymes. This compound is primarily utilized in research focused on asthma and other inflammatory diseases, providing valuable insights into therapeutic pathways targeting eosinophilic inflammation. -
TXA2 Agonist
U-46619 is a stable analogue of Thromboxane A2 (TXA2) that functions as a potent TXA2 receptor (TP) agonist. This compound also acts as a RhoA agonist, promoting RhoA activation through TXA2 receptor engagement. U-46619 is primarily utilized in research to study thromboxane signaling and its implications in cardiovascular and inflammatory responses. Its ability to selectively activate TXA2 pathways makes it an essential tool for investigating related biological processes. -
Prostaglandin
Prostaglandin D2 (PGD2) is an endogenous lipid mediator primarily involved in sleep promotion and the modulation of inflammatory responses. It is produced in various mammalian brains and is recognized for its potent ability to induce sleep and reduce inflammatory processes. PGD2 is valuable in research applications related to sleep disorders, neurobiology, and inflammation. -
Thromboxane-Prostaglandin Receptor Antagonist
Terutroban sodium is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist, exhibiting an IC50 value of 16.4 nM. This compound effectively inhibits the activity of thromboxane A2 (TXA2) and prostaglandin endoperoxide receptors, demonstrating potent antithrombotic effects. Terutroban sodium also possesses anti-atherosclerotic and anti-vasoconstrictor properties, making it valuable for research applications in cardiovascular disease and related areas. -
PGDS Inhibitor
2-Benzoylthiophene is a selective inhibitor of human hematopoietic prostaglandin D2 synthase (H-PGDS), exhibiting an IC50 value of 11.4 μM. This compound is valuable for investigating the role of prostaglandin D2 in inflammatory diseases and related research applications. Its inhibitory action on H-PGDS provides a useful tool for exploring therapeutic strategies targeting inflammatory pathways. -
EP3 Receptor Antagonist
L-798106 is a potent and highly selective antagonist of the prostanoid EP3 receptor, exhibiting a Ki value of 0.3 nM. While it demonstrates micromolar activity at the EP4 receptor with a Ki of 916 nM, it shows minimal binding affinities at the EP1 and EP2 receptors, with Ki values exceeding 5000 nM. This compound is valuable for research applications involving the modulation of EP3 receptor-mediated pathways and investigating the role of prostanoids in various physiological processes. -
EP4 Receptor Agonist
L-902688 is a potent and selective agonist of the EP4 receptor, exhibiting a Ki value of 0.38 nM and an EC50 of 0.6 nM. This compound demonstrates greater than 4,000-fold selectivity for EP4 compared to other EP and prostanoid receptors. It serves as a valuable tool for researchers investigating the role of EP4 in various biological processes and potential therapeutic applications related to inflammation and pain management. -
EP4 Receptor Antagonist
L-161982 is a selective antagonist of the EP4 receptor, effectively inhibiting the biological activity of prostaglandin E2 (PGE2). It demonstrates complete blockade of PGE2-induced ERK phosphorylation and suppresses cell proliferation in HCA-7 cells. In addition, L-161982 has been shown to reduce symptoms of collagen-induced arthritis in murine models, making it a valuable tool for studying inflammatory pathways and potential therapeutic interventions in arthritis research. -
EP2 Receptor Agonist
Omidenepag is a selective, non-prostanoid agonist of the EP2 receptor, exhibiting an EC50 of 1.1 nM. With an IC50 value of 10 nM for the human EP2 receptor, Omidenepag plays a crucial role in studying conditions associated with intraocular pressure. Its potent biological activity makes it a valuable tool for research into ocular diseases and related pathophysiological mechanisms. -
Vasodilator
Beraprost sodium is a stable, orally active prostacyclin analog that acts as a potent vasodilator. By expanding renal blood vessels and enhancing microcirculation, it holds potential for the treatment of pulmonary arterial hypertension. Additionally, Beraprost sodium features an alkyne group, enabling its use as a click chemistry reagent that can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating various biochemical applications. -
EP3 Receptor Agonist
Ricinoleic acid is a hydroxylated fatty acid and a potent agonist of the prostaglandin EP3 receptor, with an EC50 of 0.5 μM in MEG-01 cells. This compound is associated with various biological activities, including laxative effects and uterine contractions. Additionally, ricinoleic acid demonstrates both antianxiety-like and anti-inflammatory properties, making it valuable for research in pharmacology and developmental biology. Its high purity (≥99%) enhances its suitability for diverse applications, including studies related to gastrointestinal function and reproductive health. -
EP4 Antagonist
EP4 receptor antagonist 1 is a highly potent and selective competitive antagonist of the prostanoid EP4 receptor, primarily utilized in cancer immunotherapy. It exhibits strong inhibition of human and mouse EP4 receptors with IC50 values of 6.1 nM and 16.2 nM, respectively, while showing minimal activity against human EP1, EP2, and EP3 receptors, with IC50s exceeding 10 μM. This specificity makes it a valuable tool for investigating the role of EP4 in various oncological processes. -
PGD2 receptor Agonist
Prostaglandin J2 (PGJ2) is a potent agonist of the PGD2 receptors, notably hDP and hCRTH2, exhibiting Kis of 0.9 nM and 6.6 nM, respectively. It effectively stimulates intracellular cyclic AMP production with an EC50 of 1.2 nM. Beyond its receptor activity, Prostaglandin J2 is implicated in inducing oxidative stress, neuronal apoptosis, and the accumulation of ubiquitinated proteins. Its neurotoxic properties suggest a potential role in the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's. This compound is valuable for research into receptor signaling pathways and neurodegenerative mechanisms. -
Prostaglandin Receptor Inhibitor
p-Hydroxycinnamic acid is a prostaglandin receptor inhibitor that functions as a dietary phenolic compound. It demonstrates significant biological activity by inhibiting platelet activity, with IC50 values of 371 μM for thromboxane B2 production and 126 μM for lipopolysaccharide-induced prostaglandin E2 generation. This compound is often utilized in research related to inflammation, cardiovascular diseases, and platelet function studies. -
Prostacyclin Agonist
ONO 1301 is a potent prostacyclin agonist that mimics the action of prostaglandin I2. It exhibits thromboxane-synthase inhibitory activity, enhancing the production of hepatocyte growth factor (HGF) from multiple cell types. Research demonstrates that ONO 1301 effectively ameliorates ischemia-induced left ventricular dysfunction in various animal models, including mouse, rat, and pig, making it a valuable tool for studies related to cardiovascular health and regenerative medicine. -
EP1 Antagonist
SC-51322 is a selective antagonist of the prostaglandin E2 receptor subtype EP1, exhibiting a pA2 value of 8.1. This compound demonstrates significant analgesic properties, making it a valuable tool for research focused on pain mechanisms and inflammation. Its specificity for the EP1 receptor allows for the exploration of pathways involved in nociception and potential therapeutic interventions. -
EP4 Agonist
Rivenprost is a selective agonist of the prostaglandin E receptor EP4, characterized by a Ki value of 0.7 nM. It has demonstrated hepatoprotective properties and bone anabolic activity. This compound is relevant for research in areas such as liver protection, bone metabolism, and the pharmacological modulation of EP4 receptor activity. -
EP2 Receptor Agonist
Omidenepag isopropyl is a selective agonist of the EP2 receptor. Upon corneal penetration, it is converted to the active form, Omidenepag, which demonstrates high selectivity for the EP2 receptor with minimal affinity for EP1 and FP receptors. This compound is under investigation for its potential use in lowering intraocular pressure, making it a valuable candidate for glaucoma treatment research. -
Prostaglandin Derivative
Thromboxane B2 is a prostaglandin derivative primarily involved in inducing arterial contraction and promoting platelet aggregation. This biological inactive product serves as a circulating catabolite of thromboxane A2, making it relevant as a diagnostic marker for angina in both peripheral venous and coronary sinus blood. Research indicates that Thromboxane B2 levels correlate with COX-1 activity inhibition in platelets. Furthermore, in preclinical models, Thromboxane B2 has demonstrated dose-dependent effects on respiratory function, producing decreases in airflow rate and dynamic lung compliance while increasing pulmonary airway resistance, highlighting its role as a bronchoactive metabolite in the arachidonic acid bioconversion pathway. -
CRTH2/DP Receptors Dual Antagonist
Vidupiprant is a phenylacetic acid derivative that acts as a dual antagonist of CRTH2 (DP2) and prostanoid D receptors (DP1). It exhibits high potency with IC50 values of 3 nM and 4 nM in buffer, and 8 nM and 35 nM in human plasma, respectively. This compound shows promise for therapeutic applications in asthma management and related respiratory conditions. -
TXA2 Receptor Antagonist
NTP42 is a potent thromboxane A2 (TXA2) receptor antagonist, exhibiting an IC50 of 3.278 nM in inhibiting T prostanoid receptor (TP)-mediated [Ca2+] mobilization upon stimulation with the alternative TP agonist U46619. This compound is particularly relevant for research applications targeting pulmonary arterial hypertension (PAH), offering potential therapeutic avenues for addressing this condition through TXA2 modulation.
